Everything below concerns Forced degradation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
== History == In 1899, Friedrich Wilhelm Zopf reported isolating a substance from Lecidea confluens, which he named confluentin, characterised by a melting point of 147–148 °C (297–298 °F). He also found that this substance turns litmus paper red, reacts with FeCl3 to produce a red-brown colour, and decomposes into carbon dioxide, a volatile substance, and a phenol-like compound with a melting point of 52 °C upon interaction with alkali. Zopf initially proposed the formula C37H50O10 for this compound before revising it to C26H36O7, noting the updated melting point as 154 °C (309 °F). In his 1962 report of his chemical investigations into the substance, German chemist Siegfried Huneck proposed naming it 'confluentinic acid' due to the presence of the carboxylic acid functional group, aligning with the naming conventions of other lichen products. Huneck described the substance as optically inactive and noted its poor solubility in petroleum ether, ethyl acetate, and acetone, but found it readily soluble in ether, benzene, and methanol. He noted the following colour reactions: weak brownish with alcoholic FeCl3 solution, blue, green, and finally violet with potassium hydroxide and chloroform upon heating, orange to orange-red with tetrazotised benzidine, and gray-violet with p-phenylenediamine; no colouration was observed with barium hydroxide. Huneck used elemental analysis and molecular weight determination by titration to determine the molecular formula of confluentinic acid as C28H36O8.
is the water content of blood, approximately 0.825 w/v for men and 0.838 w/v for women. These calculations assume Widmark's zero-order model for the effects of metabolization, and assume that TBW is almost exactly the volume of distribution of ethanol. Using a more complex model that accounts for non-linear metabolism, Norberg found that Vd was only 84-87% of TBW. This finding was not reproduced in a newer study which found volumes of distribution similar to those in the literature.
Serine hydroxymethyltransferase (SHMT) also catalyzes the biosynthesis of glycine (retro-aldol cleavage) from serine, transferring the resulting formaldehyde synthon to 5,6,7,8-tetrahydrofolate. However, that reaction is reversible, and will convert excess glycine to serine. SHMT is a pyridoxal phosphate (PLP) dependent enzyme.
==== The phenethylamine psychedelic mescaline ==== Mescaline is sometimes described as the "first psychedelic", as it was the first to be discovered and characterized by the Western world. American physician John Raleigh Briggs, living in Texas, learned of peyote from Native Americans and Mexicans, who told him that it produced "beautiful visions" and made them journey into the "spirit world". He obtained mescal buttons from Mexico and published a journal article about trying a very low dose of them in May 1887. This article is said to have brought peyote into North American pharmacology. Briggs described the physiological symptoms of his experience, such as dramatically increased heart rate and of experiencing "intoxication". However, a modern interpretation is that Briggs simply had a severe panic attack in response to the drug. In any case, his article was read by George Davis, of Parke, Davis and Company, who then obtained the buttons from Briggs in June 1887. Parke-Davis attempted to market peyote as a cardiac stimulant and for other uses, but met with little success. The German pharmacologist Louis Lewin obtained mescal buttons from Parke-Davis during a trip to the United States in 1887 and began studying them and sharing his findings. James Mooney, the first Westerner known to have participated in a Native American peyote ceremony in 1892, distributed peyote to a number of authorities in 1894. Using these specimens, the hallucinogenic effects of peyote were first properly described by Daniel W. Prentiss and F. P. Morgan in 1895.
Changes in nearby tissue is not the only possible impact of ligand therapy, there may be immunologic responses from the target tissue that cause changes remotely. This has been dubbed the "abscopal effect". While this mechanism is not well understood, it explains the impact of other tissue, both benign and malignant, after targeted radiotherapy.
Sources: en.wikipedia.org
=== Regional chains === MEGA MART, Owner by Nongshim JangbogoFoodMart, JangbogoFoodMart is a regional supermarket chain in Korea, focusing on Gyeongsang Province. Owner by JangbogoFoodMart Co, LTD. TopMart, TopMart is a regional supermarket chain in Korea, focusing on Gyeongsang Province. Owner by SEOWON DISTRIBUTION Co., Ltd. TRIAL, TRIAL is Japan Supermarket Chain Group. South Korea Store Owner by TRIAL Korea Co., Ltd. IGA Segyero Mart
Cys530 is conserved in all amidase-active vertebrate and invertebrate PGRPs, whereas non-catalytic PGRPs (including mammalian PGLYRP1, PGLYRP3, and PGLYRP4) have serine in this position, and thus the presence of Cys or Ser in this position can be used to predict amidase activity of PGRPs. However, Cys530 and seven other amino acids that are all required for the amidase activity of PGRPs are not sufficient for the amidase activity, which requires additional so far unidentified amino acids.
Evocative/suppression testing refers to a class of tests performed where one substance is measured both before and after the administration of another substance to determine if the levels are stimulated ("evocative") or suppressed. They are most commonly performed in the evaluation of possible endocrine disorders. Certain tests are performed in the evaluation of multiple conditions, and not all listed substances may be measured in each test. Examples include:
The following is a list of women who have been elected or appointed head of state or government of their respective countries. The first list includes female presidents who are heads of state and may also be heads of government, as well as female heads of government who are not concurrently head of state, such as prime ministers. The list does not include Queens regnant who are heads of state (but not of government). Khertek Anchimaa, of the mostly unrecognized and now defunct Tuvan People's Republic, is regarded as the first elected female head of state in the world, although not in multiparty, free and fair elections. The wife of the nation's Supreme Leader, she is the first woman to be elected chairman of a country. She became the chairwoman of the country's presidium in 1940. The first woman to be elected as prime minister of a country was Sirimavo Bandaranaike of Ceylon (present-day Sri Lanka), when she led her party to victory in the July 1960 general election. The first woman to serve as president of a country was Isabel Perón of Argentina, who served as the country's vice president and succeeded to the presidency in July 1974 upon the death of her husband. In 1979, Margaret Thatcher was elected as Prime Minister of the United Kingdom, becoming both the United Kingdom's first female prime minister, and Europe's first elected female head of government.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.